AbbVie
ABBV
2,034 hedge funds and large institutions have $82.8B invested in AbbVie in 2019 Q1 according to their latest regulatory filings, with 128 funds opening new positions, 788 increasing their positions, 899 reducing their positions, and 131 closing their positions.
0.07% more ownership
Funds ownership: 69.56% → 69.63% (+0.07%)
2% less first-time investments, than exits
New positions opened: 128 | Existing positions closed: 131
1% less funds holding
Funds holding: 2,063 → 2,034 (-29)
12% less repeat investments, than reductions
Existing positions increased: 788 | Existing positions reduced: 899
13% less capital invested
Capital invested by funds: $95.6B → $82.8B (-$12.8B)
20% less call options, than puts
Call options by funds: $996M | Put options by funds: $1.25B
59% less funds holding in top 10
Funds holding in top 10: 148 → 61 (-87)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$407M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$390M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$313M |
| 4 |
Two Sigma Advisers
New York
|
+$309M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$242M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$2.21B |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$406M |
| 3 |
Morgan Stanley
New York
|
-$313M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
-$216M |
| 5 |
Aristotle Capital Management
Los Angeles,
California
|
-$190M |
ABBV Hedge Fund Activity: Q1 2019 in Review
2,034 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2019, worth a combined $82.8B — down 13% from $95.6B a quarter earlier.
Sellers outnumbered buyers: 131 funds closed out of ABBV and 128 opened new positions — a net loss of 3 holders — while 899 trimmed existing stakes and 788 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $407M. The largest seller was Capital Research Global Investors, cutting an estimated $2.21B.
- 2,034 institutional investors held AbbVie (ABBV) as of Q1 2019, down from 2,063 in Q4 2018.
- Funds reported $82.8B of AbbVie stock for Q1 2019, down 13% quarter-over-quarter.
- 128 funds opened new AbbVie positions in Q1 2019 and 131 closed out, a net change of -3 holders.
- The largest AbbVie buyer in Q1 2019 was D.E. Shaw & Co, an estimated $407M added.
- The largest AbbVie seller in Q1 2019 was Capital Research Global Investors, an estimated $2.21B sold.
Based on aggregated 13F filings for Q1 2019.